Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences especially for use as to nucleotide repeat disorders. Provided are delivery systems and tissues or organ which are targeted as sites for delivery especially for use as to nucleotide repeat disorders. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex or system especially for use as to nucleotide repeat disorders, as well as methods for the design and of such. Also provided are methods of directing CRISPR complex or system formation in eukaryotic cells especially for use as to nucleotide repeat disorders including with consideration of specificity for target recognition and avoidance of toxicity and editing or modifying a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.
1. An engineered composition for in vivo genome editing in a multicellular organism, comprising at least two CRISPR-Cas system guides and at least one Cas9 protein, or one or more vectors encoding the at least two CRISPR-Cas system guides and the at least one Cas9 protein, wherein the at least two CRISPR-Cas system guides are engineered to target at least two CRISPR-Cas complexes to at least two DNA sequences in a eukaryotic cell that together flank a nucleotide sequence comprising a defective nucleotide element, repeat or expansion to thereby mediate cleavage of the flanking DNA sequences and excision of the defective nucleotide element, repeat or expansion, and
wherein the defective nucleotide element, repeat or expansion is selected from the group consisting of: a trinucleotide repeat comprising CTG, CAG, CGG, CCG, GAA, or TTC; a tetranucleotide repeat comprising CCTG, a pentanucleotide repeat comprising ATTCT or AGAAT; a hexanucleotide repeat comprising GGGGCC; and a dodecanucleotide repeat comprising SEQ ID NO: 1 or SEQ ID NO: 2.
2. The composition of claim 1 , wherein the at least two CRISPR-Cas system guides are encoded by a first viral vector and the at least one Cas9 protein is encoded by a second viral vector.
3. The composition of claim 2 , wherein the first and second viral vectors are lentiviral vectors or recombinant AAV.
4. The composition of claim 3 , wherein the first and second viral vectors are recombinant AAV and the recombinant AAV genome comprises inverted terminal repeats (iTRs).
5. The composition of claim 4 , wherein expression of the at least one Cas9 protein is driven by the inverted terminal repeat (iTR) in the AAV genome.
6. The composition of claim 2 , wherein:
the CRISPR-Cas system guides are encoded by nucleotide sequences operably linked to a first regulatory element and the at least one Cas9 protein is encoded by a nucleotide sequence operably linked to a second regulatory element;
wherein the first regulatory element comprises a RNA polymerase type III promoter and the second regulatory element is or comprises a RNA polymerase type III promoter;
the first regulatory element comprises a U6 promoter or a H1 promoter; or
the second regulatory element comprises a ubiquitous expression promoter or a cell specific promoter.
7. The composition of claim 1 , wherein the composition comprises a selection marker comprising a FLAG-tag.
8. The composition of claim 1 , wherein the composition is delivered via injection; or wherein the composition or a part thereof is delivered via a liposome, a nanoparticle, an exosome or a microvesicle.
9. The composition of claim 1 , wherein the at least one Cas9 protein comprises SpCas9 or SaCas9, or wherein the at least one Cas9 protein comprises one or more mutations.
10. The composition of claim 1 , wherein the cell comprises a mammalian brain or central nervous tissue cell.
11. The composition of claim 1 , wherein the defective nucleotide element, repeat or expansion gives rise to a condition selected from one or more of: a Fragile X (FXS); Spinocerebellar ataxia type-12 (SCA12); Friedreich Ataxia; Myotonic Dystrophy type-1 (DM1); Spinocerebellar ataxia type-8 (SCAB); Spinocerebellar ataxia type-10 (SCA10);
Spinocerebellar ataxia type-31 (SCA31); Spinocerebellar ataxia type-1 (SCA1); Spinocerebellar ataxia type-2 (SCA2); Spinocerebellar ataxia type-3 (SCA3); Spinocerebellar ataxia type-6 (SCA6); Spinocerebellar ataxia type-7 (SCAT); Spinocerebellar ataxia type-17 (SCA17); and
Huntington's Disease (HD).
12. The composition of claim 1 , wherein the defective nucleotide element, repeat or expansion gives rise to a condition selected from one or more of: a Fragile X Tremor Ataxia (FXTAS); Unverricht-Lundborg disease (EPM1); Amyotrophic Lateral Sclerosis (ALS); Fronto Temporal Dementia (FTD); Myotonic Dystrophy type-2 (DM2); Oculopharyngeal muscular dystrophy (OPMD); Dentatorubral-pallidoluysian atrophy (DRPLA); Spinobulbar muscular atrophy (SBMA); and Huntington's disease like type-2 (HDL2).
13. The composition of claim 1 , further comprising at least one additional system guide capable of hybridizing to a nucleotide sequence encoding a component of the at least two CRISPR-Cas complexes=, to diminish or eliminate functional expression of the system or complex, whereby the system or complex is Self-Inactivating.
14. The composition of claim 1 , wherein excision of the defective nucleotide element, repeat or expansion produces a phenotypic change in the multicellular organism.
15. The composition of claim 1 , wherein the at least two CRISPR-Cas system guides and the at least one Cas9 protein are encoded by a single vector.
16. The composition of claim 1 , wherein the defective nucleotide element, repeat or expansion is a trinucleotide repeat comprising CAG or CTG.
17. The composition of claim 1 , wherein the defective nucleotide element, repeat or expansion is in the coding sequence of a HTT gene.
18. The composition of claim 13 , wherein the additional system guide is capable of hybridizing to a nucleotide sequence encoding the at least one Cas9 protein.
19. A method of treating or inhibiting a condition in a cell or treating a disease or disorder in a patient, said cell or patient having a defective nucleotide element or trinucleotide repeat or other nucleotide repeat element or nucleotide expansion, comprising delivering the composition of claim 1 .
20. The method of claim 19 , wherein the disease or disorder comprises a brain disease or disorder or a central nervous system disease or disorder or any of the conditions selected from one or more of: Fragile X (FXS); Spinocerebellar ataxia type-12 (SCA12); Friedreich Ataxia; Myotonic Dystrophy type-1 (DM1); Spinocerebellar ataxia type-8 (SCA8); Spinocerebellar ataxia type-10 (SCA10);
Spinocerebellar ataxia type-31 (SCA31); Spinocerebellar ataxia type-1 (SCA1); Spinocerebellar ataxia type-2 (SCA2); Spinocerebellar ataxia type-3 (SCA3); Spinocerebellar ataxia type-6 (SCA6);
Spinocerebellar ataxia type-7 (SCA7); Spinocerebellar ataxia type-17 (SCA17); Huntington's Disease (HD);
Fragile X Tremor Ataxia (FXTAS); Unverricht-Lundborg disease (EPM1); Amyotrophic Lateral Sclerosis (ALS); Fronto Temporal Dementia (FTD); Myotonic Dystrophy type-2 (DM2); Oculopharyngeal muscular dystrophy (OPMD); Dentatorubral-pallidoluysian atrophy (DRPLA); Spinobulbar muscular atrophy (SBMA); and Huntington's disease like type-2 (HDL2).
21. An engineered composition for in vivo genome editing in a multicellular organism, comprising an AAV vector encoding at least two CRISPR-Cas system guides and at least one Cas9 protein, wherein the at least two CRISPR-Cas system guides are engineered to target at least two CRISPR-Cas complexes to at least two DNA sequences in a eukaryotic cell that together flank a nucleotide sequence comprising a defective nucleotide element, repeat or expansion to thereby mediate cleavage of the flanking DNA sequences and excision of the defective nucleotide element, repeat or expansion, and
wherein the defective nucleotide element, repeat or expansion is selected from the group consisting of: a trinucleotide repeat comprising CTG, CAG, CGG, CCG, GAA, or TTC; a tetranucleotide repeat comprising CCTG, a pentanucleotide repeat comprising ATTCT or AGAAT; a hexanucleotide repeat comprising GGGGCC; and a dodecanucleotide repeat comprising SEQ ID NO: 1 or SEQ ID NO: 2.